EUR 14.6
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 12.41 Million GBP | 171.7% |
2022 | 4.56 Million GBP | 51.95% |
2021 | 3 Million GBP | 27.9% |
2020 | 2.35 Million GBP | -22.79% |
2019 | 3.04 Million GBP | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q4 | 12.41 Million GBP | 52.41% |
2023 FY | 12.41 Million GBP | 171.7% |
2023 Q2 | 8.14 Million GBP | 78.27% |
2022 FY | 4.56 Million GBP | 51.95% |
2022 Q4 | 4.56 Million GBP | 57.77% |
2022 Q2 | 2.89 Million GBP | -3.69% |
2021 FY | 3 Million GBP | 27.9% |
2021 Q4 | 3 Million GBP | 59.02% |
2021 Q2 | 1.89 Million GBP | -19.57% |
2020 Q4 | 2.35 Million GBP | -86.64% |
2020 FY | 2.35 Million GBP | -22.79% |
2020 Q2 | 17.6 Million GBP | 0.0% |
2019 FY | 3.04 Million GBP | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BioNTech SE | 2.76 Billion EUR | 99.55% |
CureVac N.V. | 271.53 Million EUR | 95.428% |
Biotest Aktiengesellschaft | 945.4 Million EUR | 98.687% |
Biotest Aktiengesellschaft | 945.4 Million EUR | 98.687% |
BRAIN Biotech AG | 47.92 Million EUR | 74.096% |
Formycon AG | 387.61 Million EUR | 96.797% |
Heidelberg Pharma AG | 21.01 Million EUR | 40.923% |
Medigene AG | 10.65 Million EUR | -16.563% |